Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jade Mondesir"'
Autor:
Crystal Cabral, Katherine Molloy, Joseph P. Nkolola, Alison L. Hill, David Jetton, Kathryn E. Stephenson, Maria G. Pau, Nelson L. Michael, Hanneke Schuitemaker, Peter Abbink, Lauren Peter, Jinyan Liu, Abishek Chandrashekar, Romas Geleziunas, Jeffrey M. Gerold, Galit Alter, Merlin L. Robb, Jessica Jimenez, Mark G. Lewis, Dan H. Barouch, Benjamin C. Lee, Jerome H. Kim, Joseph Hesselgesser, David Ng’ang’a, Erica N. Borducchi, Shanell Mojta, Amanda L. Brinkman, Jade Mondesir
Publikováno v:
Nature
The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of HIV-1 research. However, little evidence exists that the viral reservoir can be sufficiently targeted to improve virolog
Autor:
Dan H. Barouch, Crystal Cabral, Jeffrey D. Lifson, Mayuri Shetty, Dennis R. Burton, Rafick-Pierre Sekaly, Abishek Chandrashekar, Wendeline Wagner, Peter Abbink, Lauren Peter, Chantelle Baker, Arnaud D. Colantonio, Jinyan Liu, Amanda L. Brinkman, Jade Mondesir, Yuan Li, Patricia B. Giglio, Erica N. Borducchi, Mark G. Lewis, Brian Berkemeier, Benjamin C. Lee, Elizabeth Chipriano, Khader Ghneim, Courtney Gittens, William J. Bosche, Devin Sok, Wenjun Li, Kelli Oswald, Jessica Jimenez
Publikováno v:
Science. 353:1045-1049
HIV-1–specific broadly neutralizing antibodies (bNAbs) can protect rhesus monkeys against simian-human immunodeficiency virus (SHIV) challenge. However, the site of antibody interception of virus and the mechanism of antibody-mediated protection re
Autor:
Thomas P. Monath, Quazim A. Alayo, Christine A. Bricault, Jessica Jimenez, Daniel D. Pinschewer, Dan H. Barouch, Jennifer L. Shields, Bastien Mangeat, Gerhard Fuhrmann, Klaus Orlinger, Pablo Penaloza MacMaster, Abishek Chandrashekar, Anders Lilja, Matthew Lim, Jade Mondesir, M. Justin Iampietro, Nicholas M. Provine, Crystal Cabral, Andreas Aspoeck, Joseph M Cabral, Michael S. Seaman
Publikováno v:
Vaccine. 35(1)
An important focus in vaccine research is the design of vaccine vectors with low seroprevalence and high immunogenicity. Replication-incompetent lymphocytic choriomeningitis virus (rLCMV) vectors do not elicit vector-neutralizing antibody responses,